Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G; EMISEP Study Group.

Mult Scler. 2018 Jun 1:1352458518781999. doi: 10.1177/1352458518781999. [Epub ahead of print]

PMID:
29909771
2.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 May 28. doi: 10.1007/s40263-018-0528-2. [Epub ahead of print]

PMID:
29808469
3.

Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.

Biotti D, Lerebours F, Bonneville F, Ciron J, Clanet M, Brassat D.

Mult Scler. 2018 May 1:1352458518765677. doi: 10.1177/1352458518765677. [Epub ahead of print]

PMID:
29741120
4.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B; SFSEP and OFSEP groups.

Mult Scler. 2018 May 1:1352458518772748. doi: 10.1177/1352458518772748. [Epub ahead of print]

PMID:
29722639
5.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
6.

Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy.

Ciron J, Colin O, Rosier MP, Lapeyrie S, Biotti D, Brassat D, Neau JP.

Mult Scler. 2018 Apr 1:1352458517743092. doi: 10.1177/1352458517743092. [Epub ahead of print]

PMID:
29676204
7.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30.

PMID:
29606320
8.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
9.

Radiologically isolated syndrome in children: Clinical and radiologic outcomes.

Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e395. doi: 10.1212/NXI.0000000000000395. eCollection 2017 Nov.

10.

Paediatric optic neuritis: factors leading to unfavourable outcome and relapses.

Averseng-Peaureaux D, Mizzi M, Colineaux H, Mahieu L, Pera MC, Brassat D, Chaix Y, Berard E, Deiva K, Cheuret E; Kidbiosep study group.

Br J Ophthalmol. 2018 Jun;102(6):808-813. doi: 10.1136/bjophthalmol-2016-309978. Epub 2017 Sep 13.

PMID:
28903961
11.

Reply.

Fissolo N, Pignolet B, Brassat D, Comabella M.

Ann Neurol. 2017 Oct;82(4):647-648. doi: 10.1002/ana.25039. Epub 2017 Oct 4. No abstract available.

PMID:
28869673
12.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
13.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

14.

Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.

Le Berre L, Rousse J, Gourraud PA, Imbert-Marcille BM, Salama A, Evanno G, Semana G, Nicot A, Dugast E, Guérif P, Adjaoud C, Freour T, Brouard S, Agbalika F, Marignier R, Brassat D, Laplaud DA, Drouet E, Van Pesch V, Soulillou JP.

Clin Immunol. 2017 Jul;180:128-135. doi: 10.1016/j.clim.2017.05.006. Epub 2017 May 18.

15.

A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation.

Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Nixon DF, Vercauteren J, Brassat D, Liblau R, Vandamme AM, Galvão-Castro B, Van Weyenbergh J.

Front Immunol. 2017 Feb 14;8:97. doi: 10.3389/fimmu.2017.00097. eCollection 2017.

16.

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.

Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L; PGRx-AD Study Group.

J Autoimmun. 2017 May;79:84-90. doi: 10.1016/j.jaut.2017.01.005. Epub 2017 Feb 9.

17.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

18.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
19.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
20.

Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients.

Voltzenlogel V, Ernst A, de Sèze J, Brassat D, Manning L, Berna F.

Conscious Cogn. 2016 Oct;45:200-209. doi: 10.1016/j.concog.2016.09.010. Epub 2016 Sep 19.

PMID:
27656786
21.

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.

Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network; RISC.

J Neurol Sci. 2016 Sep 15;368:334-6. doi: 10.1016/j.jns.2016.07.052. Epub 2016 Jul 25.

PMID:
27538659
22.

Teaching NeuroImages: Painful diplopia and Crohn disease: Think about orbital myositis.

Biotti D, Toulemonde P, Brassat D, Bonneville F.

Neurology. 2016 Aug 16;87(7):e68-9. doi: 10.1212/WNL.0000000000002987. No abstract available.

PMID:
27527545
23.

Assessment of a program to encourage the multidisciplinary management of urinary disorders in multiple sclerosis.

Castel-Lacanal E, Gamé X, Clanet M, De Boissezon X, Brassat D, Rischmann P, Marque P.

Neurourol Urodyn. 2017 Mar;36(3):706-709. doi: 10.1002/nau.23002. Epub 2016 Mar 29.

PMID:
27028504
24.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
25.

Teaching Video NeuroImages: Alternating skew deviation with abducting hypertropia following superior colliculus infarction.

Biotti D, Barbieux M, Brassat D.

Neurology. 2016 Mar 1;86(9):e93-4. doi: 10.1212/WNL.0000000000002425. No abstract available.

PMID:
26928363
26.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195. eCollection 2016 Feb.

27.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

28.

CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS.

Nat Rev Neurol. 2016 Feb;12(2):95-105. doi: 10.1038/nrneurol.2015.248. Epub 2016 Jan 18. Review.

PMID:
26782333
29.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

30.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
31.

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP.

Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.

PMID:
26362900
32.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
33.

Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.

Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, Saiz A, Marignier R.

Mult Scler. 2016 Mar;22(3):312-9. doi: 10.1177/1352458515591071. Epub 2015 Jul 24.

PMID:
26209592
34.

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.

J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21.

PMID:
26194198
35.

Peripheral late reactivation of a previously typical monofocal Baló's concentric sclerosis lesion.

Pique J, Bonneville F, Brassat D, Peaureaux D, Benaiteau M, Dumas H, Fabre N, Clanet M, Biotti D.

Mult Scler. 2015 Jul;21(8):1080-3. doi: 10.1177/1352458515586087. Epub 2015 May 26.

PMID:
26014609
36.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
37.

A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.

Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, Pertel T, Stankiewicz JM, Martinelli V, Rodegher M, Weiner HL, Brassat D, Benoist C, Patsopoulos NA, Comi G, Elyaman W, Martinelli Boneschi F, De Jager PL.

Ann Neurol. 2015 Jul;78(1):115-27. doi: 10.1002/ana.24429. Epub 2015 May 14.

PMID:
25914168
38.

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.

Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E.

Mult Scler. 2015 Sep;21(10):1251-61. doi: 10.1177/1352458514561906. Epub 2015 Feb 19.

PMID:
25698171
39.

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.

Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M.

Brain. 2015 Apr;138(Pt 4):918-31. doi: 10.1093/brain/awv017. Epub 2015 Feb 13.

PMID:
25688078
40.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
41.

Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.

Martin-Blondel G, Bauer J, Uro-Coste E, Biotti D, Averseng-Peaureaux D, Fabre N, Dumas H, Bonneville F, Lassmann H, Marchou B, Liblau RS, Brassat D.

Acta Neuropathol. 2015 Mar;129(3):463-5. doi: 10.1007/s00401-015-1383-6. Epub 2015 Jan 15. No abstract available.

PMID:
25589222
42.

NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.

Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, Fernández O, Oliver B, Zettl U, Brassat D, Killestein J, Lechner-Scott J, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M.

Brain. 2015 Mar;138(Pt 3):644-52. doi: 10.1093/brain/awu388. Epub 2015 Jan 12.

43.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
44.

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, Fernández O, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec.

45.

Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.

Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.

Mult Scler. 2015 Apr;21(5):671-2. doi: 10.1177/1352458514549823. Epub 2014 Oct 10. No abstract available.

PMID:
25305251
46.

A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS.

Taieb G, Uro-Coste E, Clanet M, Lassmann H, Benouaich-Amiel A, Laurent C, Delisle MB, Labauge P, Brassat D.

J Neurol Sci. 2014 Sep 15;344(1-2):224-6. doi: 10.1016/j.jns.2014.06.015. Epub 2014 Jun 18. No abstract available.

PMID:
24990651
47.

[Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects].

Lionnet C, Carra C, Ayrignac X, Levade T, Gayraud D, Castelnovo G, Besson G, Androdias G, Vukusic S, Confavreux C, Zaenker C, De Seze J, Collongues N, Blanc F, Tranchant C, Wallon D, Hannequin D, Gerdelat-Mas A, Brassat D, Clanet M, Zephir H, Outteryck O, Vermersch P, Labauge P.

Rev Neurol (Paris). 2014 Jun-Jul;170(6-7):445-53. doi: 10.1016/j.neurol.2014.01.675. Epub 2014 Apr 16. French.

PMID:
24746394
48.

Multiple sclerosis and pregnancy.

Bodiguel E, Bensa C, Brassat D, Laplaud D, Le Page E, Ouallet JC, Zephir H, De Seze J; Groupe de Réflexion sur la Sclérose en Plaques.

Rev Neurol (Paris). 2014 Apr;170(4):247-65. doi: 10.1016/j.neurol.2013.09.010. Epub 2014 Mar 28.

PMID:
24684929
49.

Radiologically isolated syndrome: 5-year risk for an initial clinical event.

Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, Keegan BM, Donlon S, Hua le H, Vidal-Jordana A, Montalban X, Rovira A, Tintoré M, Amato MP, Brochet B, de Seze J, Brassat D, Vermersch P, De Stefano N, Sormani MP, Pelletier D, Lebrun C; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone de la Sclérose en Plaques (CFSEP).

PLoS One. 2014 Mar 5;9(3):e90509. doi: 10.1371/journal.pone.0090509. eCollection 2014.

50.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807

Supplemental Content

Loading ...
Support Center